UnknownPHASE1, PHASE2NCT03750071

VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma

Studying Astrocytoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Vaximm GmbH
Principal Investigator
Wolfgang Wick, MD, MD
University Clinics Heidelberg
Intervention
VXM01(biological)
Enrollment
30 target
Eligibility
18 years · All sexes
Timeline
20182022

Study locations (2)

Collaborators

Merck KGaA, Darmstadt, Germany · Pfizer

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03750071 on ClinicalTrials.gov

Other trials for Astrocytoma

Additional recruiting or active studies for the same condition.

See all trials for Astrocytoma

← Back to all trials